The New York Times ran an editorial today about a new research program announced by Pres. Obama that will test a drug’s ability to prevent the onset of Alzheimer’s disease before any symptoms appear.
The trial does not adhere to conventional guidelines but instead focuses on members of an extended family in Colombia who carry a rare genetic mutation that causes them to develop Alzheimer’s in their 40’s.
The cost of this study will reach more than $100 million and is being financed both privately and publicly. It is evidence of how much manufacturers and reserach groups are dedicated to finding more effective ways to combat this debilitating and prevalent disease.
-Jaime Venditti, 5/21/12